2.47 USD
↘ 0.01 (0.40%)AT CLOSE (11:59 AM EDT)
Kiora Pharmaceuticals, Inc. Common Stock
KPRXNASDAQ • USD
2.37
↘ 0.10 (4.05%)
POST MARKET (AS OF 07:36 PM EDT)
Post Market
AS OF 07:36 PM EDT
2.37
↘ 0.10 (4.05%)
Market: CLOSED
Open?$2.50
High?$2.60
Low?$2.37
Prev. Close?$2.48
Volume?74.9K
Avg. Volume?965.5K
VWAP?$2.46
Rel. Volume?0.08x
Bid / Ask
Bid?$2.37 × 500
Ask?$2.41 × 200
Spread?$0.04
Midpoint?$2.39
Valuation & Ratios
Market Cap?9.8M
Shares Out?4.0M
Float?2.7M
Float %?74.4%
P/E Ratio?N/A
P/B Ratio?0.61
EPS?-$2.74
Dividend?0.00%
Ex-Dividend?N/A
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?5.99Strong
Quick Ratio?5.99Strong
Cash Ratio?2.39Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUED
Score100/100
P/E?N/A▾
P/B?0.61CHEAP▾
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-0.1CHEAP▾
EV/Sales?N/A▾
Returns & Efficiency
ROE?-67.2%WEAK▾
ROA?-44.7%WEAK▾
Cash Flow & Enterprise
FCF?$-10071965
Enterprise Value?$1.1M
Related Companies
Loading...
News
Profile
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
Employees
13
Market Cap
9.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-02-13
Address
169 SAXONY RD.
ENCINITAS, CA 92024
Phone: 858-224-9600
ENCINITAS, CA 92024
Phone: 858-224-9600